Delivery Order SPE2DR25D1100-SPE2DR26FDD3A
Award Date 2/3/26
Potential Completion Date 2/4/26
Potential Value $6.4K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $6,133.27 to Amerisourcebergen Drug Corp for Zepbound 5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. The award was made on January 21, 2026, with an ultimate completion date of January 22, 2026, and represents a firm fixed-price delivery order with no set-aside designation. The contract was competitively awarded to Amerisourcebergen Drug Corp, which maintains its corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $2,599.65 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen (0.5 ml), a glucagon-like peptide-1 receptor agonist used for weight management and diabetes treatment. The award, issued on January 28, 2026, with a completion date of January 29, 2026, represents a firm fixed-price purchase under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,871.10 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens on January 6, 2026. This firm fixed-price delivery order, which is expected to be completed by January 7, 2026, represents a purchase of the GLP-1 receptor agonist medication used for weight management. The contract carries no set-aside designation, indicating it was awarded through full and open competition. AmerisourceBergen Drug Corp, a...
- The Defense Logistics Agency has awarded a delivery order valued at $2,425.15 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens, a glucagon-like peptide-1 (GLP-1) receptor agonist used in diabetes and weight management treatment. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and is scheduled for completion by July 24, 2025. The award was issued on July 23, 2025, with performance to be executed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,906.45 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injection on October 23, 2025, with an ultimate completion date of October 24, 2025. This non-competitive, firm fixed-price delivery order represents a single shipment of the GLP-1 receptor agonist medication used for weight management. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, leveraging the...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order was issued on September 3, 2025, with an ultimate completion date of September 4, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a $17,648.61 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 ml pen injectors on January 20, 2026, with completion targeted for January 21, 2026. The contract was competitively awarded with no set-aside designation and identifies Conshohocken, Pennsylvania as the place of performance, which serves as the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's parent...
- The Defense Logistics Agency awarded a delivery order valued at $1,107.42 to AmerisourceBergen Drug Corp for Zepbound 12.5 mg/0.5 mL pen (0.5 mL), a GLP-1 receptor agonist medication used for weight management. The award, issued on December 17, 2025, with an ultimate completion date of December 18, 2025, represents a firm fixed-price delivery order under a non-competitive set-aside contract. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,906.47 for Zepbound 2.5 mg/0.5 ml pen (0.5 ml), a GLP-1 receptor agonist medication used for weight management. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $1,560.27 delivery order to AmerisourceBergen Drug Corp on January 30, 2026, for the supply of Zepbound 7.5 mg/0.5 mL pen (0.5 mL), a GLP-1 receptor agonist medication used in diabetes and weight management treatment. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of February 2, 2026. The contract will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This...